Ashita Tolwani

Publications (3)12.97 Total impact

• Article: Regional citrate anticoagulation for continuous renal replacement therapy: the better alternative?

  Ashita Tolwani, Keith M Wille
  American Journal of Kidney Diseases 06/2012; 59(6):745-7. · 5.43 Impact Factor
• Article: Advances in continuous renal replacement therapy: citrate anticoagulation update.

  Ashita Tolwani, Keith M Wille
  [show abstract] [hide abstract]
  ABSTRACT: Because of the potential side effects of heparin, methods of regional citrate anticoagulation (RCA) for continuous renal replacement therapy (CRRT) have been gaining wider acceptance with the development of simplified and safer protocols. Advantages of RCA include the avoidance of systemic anticoagulation and heparin-induced thrombocytopenia. The disadvantage is that citrate can add complexity and labor intensity to CRRT. Frequent monitoring of electrolytes, ionized calcium, and acid-base status is required, due to the potential for hypernatremia, metabolic alkalosis, and systemic ionized hypocalcemia. If properly monitored, complications associated with RCA are uncommon. A variety of methods of delivering RCA are described in the literature. Overall, studies of RCA, as compared to unfractionated heparin, report better filter survival times and less bleeding. In this section, we summarize the characteristics of citrate as an anticoagulant and provide an update of citrate use in CRRT.
  Blood Purification 01/2012; 34(2):88-93. · 2.10 Impact Factor
• Article: Citrate-based replacement solutions with continuous venovenous hemofiltration: not as simple as it sounds.

  Ashita Tolwani, Keith M Wille
  American Journal of Kidney Diseases 07/2006; 47(6):1086; author reply 1086-7. · 5.43 Impact Factor